JP2007500176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500176A5 JP2007500176A5 JP2006521656A JP2006521656A JP2007500176A5 JP 2007500176 A5 JP2007500176 A5 JP 2007500176A5 JP 2006521656 A JP2006521656 A JP 2006521656A JP 2006521656 A JP2006521656 A JP 2006521656A JP 2007500176 A5 JP2007500176 A5 JP 2007500176A5
- Authority
- JP
- Japan
- Prior art keywords
- water
- drug
- pharmaceutical composition
- soluble
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000002253 acid Substances 0.000 claims 14
- 229920003086 cellulose ether Polymers 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 4
- 229920000609 methyl cellulose Polymers 0.000 claims 4
- 239000001923 methylcellulose Substances 0.000 claims 4
- 235000010981 methylcellulose Nutrition 0.000 claims 4
- 230000007928 solubilization Effects 0.000 claims 4
- 238000005063 solubilization Methods 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000001630 malic acid Substances 0.000 claims 2
- 235000011090 malic acid Nutrition 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-L isophthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC(C([O-])=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-L 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000006069 physical mixture Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317663.3A GB0317663D0 (en) | 2003-07-29 | 2003-07-29 | Pharmaceutical composition |
| PCT/GB2004/003241 WO2005011647A2 (en) | 2003-07-29 | 2004-07-27 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500176A JP2007500176A (ja) | 2007-01-11 |
| JP2007500176A5 true JP2007500176A5 (https=) | 2007-08-16 |
Family
ID=27799353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521656A Pending JP2007500176A (ja) | 2003-07-29 | 2004-07-27 | 医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070141141A1 (https=) |
| EP (1) | EP1651233A2 (https=) |
| JP (1) | JP2007500176A (https=) |
| GB (1) | GB0317663D0 (https=) |
| WO (1) | WO2005011647A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| JP5382334B2 (ja) * | 2008-09-19 | 2014-01-08 | ブラザー工業株式会社 | インクジェット記録用水性インクおよび水性インクセット |
| JP5815554B2 (ja) * | 2009-12-16 | 2015-11-17 | ダウ グローバル テクノロジーズ エルエルシー | メチルセルロースをｓｐｆおよび／またはｐｐｄの上昇剤として組入れるサンスクリーン組成物ならびに方法 |
| JP4574742B1 (ja) * | 2010-04-08 | 2010-11-04 | 有限会社ミールジャパン | プロポリス組成物 |
| WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
| US20180000827A1 (en) * | 2014-12-19 | 2018-01-04 | Synthon B.V. | Pharmaceutical composition comprising gefitinib |
| KR102369405B1 (ko) * | 2015-06-04 | 2022-03-02 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
| JP6585193B2 (ja) * | 2015-12-28 | 2019-10-02 | 沢井製薬株式会社 | ゲフィチニブ含有錠剤 |
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| WO2017223018A1 (en) * | 2016-06-23 | 2017-12-28 | Dow Global Technologies Llc | Esterified cellulose ethers comprising trimellityl groups |
| BR112020000011A2 (pt) | 2017-07-11 | 2020-07-21 | Qualicaps Co., Ltd. | cápsula dura entérica |
| KR20210022716A (ko) | 2018-06-22 | 2021-03-03 | 쿠오리카프스 가부시키가이샤 | 장용성 경질 캡슐 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
| US4178376A (en) * | 1977-01-21 | 1979-12-11 | Interx Research Corporation | Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9207988D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Topical composition |
| AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| AU680019B2 (en) * | 1993-08-30 | 1997-07-17 | Warner-Lambert Company Llc | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| DE59500788D1 (de) * | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AU743024B2 (en) * | 1997-03-05 | 2002-01-17 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| NZ527585A (en) * | 2001-02-15 | 2005-04-29 | Tanabe Seiyaku Co | Tablets quickly disintegrated in oral cavity |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| BRPI0307786B8 (pt) * | 2002-02-26 | 2021-05-25 | Astrazeneca Ab | composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água |
| KR20040086452A (ko) * | 2002-02-26 | 2004-10-08 | 아스트라제네카 아베 | 항암 화합물 ｚｄ1839의 신규한 결정질 형태 |
-
2003
- 2003-07-29 GB GBGB0317663.3A patent/GB0317663D0/en not_active Ceased
-
2004
- 2004-07-27 WO PCT/GB2004/003241 patent/WO2005011647A2/en not_active Ceased
- 2004-07-27 JP JP2006521656A patent/JP2007500176A/ja active Pending
- 2004-07-27 US US10/565,100 patent/US20070141141A1/en not_active Abandoned
- 2004-07-27 EP EP04743569A patent/EP1651233A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500176A5 (https=) | ||
| ES2731601T3 (es) | Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo | |
| JP5837732B2 (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| KR102695402B1 (ko) | 중수소화 돔페리돈 조성물, 방법, 및 제조 | |
| WO2011110939A2 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| JP2013100334A (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
| CN103096881A (zh) | 含有具有不愉快味道的药物的膜制剂 | |
| BR112018001859B1 (pt) | Comprimido, e, método para produzir um comprimido | |
| CN101412690A (zh) | 西洛多辛的药用酸加成盐及其制备方法和药物应用 | |
| JP2008533127A5 (https=) | ||
| CN103833712B (zh) | 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途 | |
| CN104244952A (zh) | 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途 | |
| JP2015531749A5 (https=) | ||
| CN118161464A (zh) | 含阿司匹林的药物制剂及其制备方法和应用 | |
| JP5805891B2 (ja) | ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミドを含有する錠剤 | |
| CN105434398B (zh) | 一种雷贝拉唑肠溶微丸及其制备方法 | |
| JP2007504223A5 (https=) | ||
| CN104093400A (zh) | 稳定的无定形雷特格韦钾盐预混料及其制备方法 | |
| JP2007504222A5 (https=) | ||
| CN113924145A (zh) | 痛风或高尿酸血症的治疗药 | |
| CN104473895A (zh) | 拉莫三嗪口腔崩解缓释片 | |
| WO2000043041A1 (fr) | Compositions medicamenteuses presentant une meilleure absorption orale | |
| RU2007101521A (ru) | Моногидрат натриевой соли s-тенатопразола и его применение в качестве ингибитора протонного насоса | |
| JP6903252B2 (ja) | キサンチンオキシダーゼ阻害剤含有腸溶性製剤 | |
| CN103788044B (zh) | 硝克柳胺化合物晶i型、其制法和其药物组合物与用途 |